Corvus Pharmaceuticals Presents Interim Data from Phase 1b/2 Trial of Ciforadenant for Metastatic Renal Cell Cancer at ESMO Congress 2025

Corvus Pharmaceuticals will present interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer at the European Society for Medical Oncology Congress 2025. The trial, conducted by the Kidney Cancer Research Consortium, has enrolled 50 patients with newly diagnosed or recurrent stage IV clear cell RCC. The interim data shows that the triplet therapy with ciforadenant, ipilimumab, and nivolumab is feasible and well tolerated. The presentation highlights the trial's patient demographics and clinical characteristics.